Chest
Clinical InvestigationsInterstitial Pneumonitis in Association with Polymyositis and Dermatomyositis
Section snippets
MATERIALS AND METHODS
The records of all patients with a diagnosis of polymyositis or dermatomyositis seen at the Mayo Clinic during the interval 1965 through 1971 were searched (because of the wide overlap between polymyositis and dermatomyositis clinically, we have chosen to consider them as one group, PM-DM). Patients with clinical or laboratory evidence suggesting other associated collagen or vascular diseases were excluded. Diagnoses were confirmed by increased! values for serum glutamic-oxalacetic transaminase
RESULTS
Two hundred thirteen cases (139 in women and 74 in men) fulfilled the above criteria for a diagnosis of PM-DM. Of these, in ten (5 percent) there was prominent roentgenographic evidence of parenchymal pulmonary disease.
The ten patients were equally divided as to sex (Table 1). The mean age at onset of PM-DM or related pulmonary disease was 55 years (range, 31 to 76 years). Malignant neoplastic disease was not found in any case prior to the onset of the illness or on subsequent follow-up. The
DISCUSSION
Hepper et al2 noted three mechanisms for pulmonary complications in PM-DM: (1) aspiration of esophageal contents secondary to esophageal motility disorders; (2) hypoventilation and retention of secretions secondary to respiratory muscle weakness; and (3) parenchymal pulmonary disease in the form of IPF. In addition, with the increasing use of corticosteroids and certain other immunosuppressive agents, there are two possible iatrogenic mechanisms for pulmonary complications: (1) opportunistic
REFERENCES (9)
- et al.
Three types of pulmonary involvement in polymyositis
Med Clin North Am
(1964) - et al.
Interstitial pneumonitis in dermatomyositis
JAMA
(1956) - et al.
Pulmonary fibrosis masking polymyositis: Remission with corticosteroid therapy
JAMA
(1972) - et al.
Dermatomyositis associated with subacute pulmonary fibrosis
Arch Dermatol
(1966)
Cited by (144)
2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease
2021, Respiratory InvestigationMyositis-Associated Interstitial Lung Disease
2021, Encyclopedia of Respiratory Medicine, Second EditionInterstitial Lung Disease in the Connective Tissue Diseases
2018, Interstitial Lung DiseaseManagement of Myositis-Related Interstitial Lung Disease
2016, ChestCitation Excerpt :Prednisone is the historical cornerstone of initial treatment in myositis-related ILD and is still a commonly used approach. The use of prednisone goes back > 30 years to an early case series26 of 10 patients with myositis-related ILD. At the time, treatment with prednisone showed a subjective amelioration of symptoms and improved chest radiography and pulmonary function test (PFT) results in patients who had an acute presentation of respiratory symptoms.
Manuscript received September 4; accepted October 17.